Jonathan Karnon

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi request reprint Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer
    Jonathan Karnon
    University of Sheffield, Health Economics and Decision Science, School of Health and Related Research, Regent Street, Sheffield, S1 4DA, UK
    Expert Rev Pharmacoecon Outcomes Res 7:143-53. 2007
  2. pmc Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis
    J Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Br J Cancer 97:479-85. 2007
  3. ncbi request reprint Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Pharmacoeconomics 24:237-50. 2006
  4. ncbi request reprint Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, England
    Pharmacoeconomics 24:215-32. 2006
  5. ncbi request reprint A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK
    J Karnon
    School of Health and Related Research, University of Sheffield, Regent Court, Regent Street, Sheffield, S1 4DA, UK
    Int J Cardiol 109:307-16. 2006
  6. ncbi request reprint Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK
    Jon Karnon
    School of Health and Related Research ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    Curr Med Res Opin 21:101-12. 2005
  7. ncbi request reprint Developing a relativities approach to valuing the prevention of non-fatal work-related accidents and ill health
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, UK
    Health Econ 14:1103-15. 2005
  8. ncbi request reprint A critique and impact analysis of decision modeling assumptions
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Med Decis Making 27:491-9. 2007
  9. ncbi request reprint A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer
    J Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Ann Oncol 14:1629-33. 2003
  10. ncbi request reprint Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation
    Jonathan Karnon
    Health Economics Research Group, Brunel University, UK
    Health Econ 12:837-48. 2003

Detail Information

Publications22

  1. ncbi request reprint Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer
    Jonathan Karnon
    University of Sheffield, Health Economics and Decision Science, School of Health and Related Research, Regent Street, Sheffield, S1 4DA, UK
    Expert Rev Pharmacoecon Outcomes Res 7:143-53. 2007
    ..Comparisons between the aromatase inhibitors are hampered as none of the clinical trials included a direct comparison, although an ongoing trial is addressing this issue...
  2. pmc Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis
    J Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Br J Cancer 97:479-85. 2007
    ....
  3. ncbi request reprint Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Pharmacoeconomics 24:237-50. 2006
    ..The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate the lifetime cost effectiveness of letrozole in this setting...
  4. ncbi request reprint Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, England
    Pharmacoeconomics 24:215-32. 2006
    ..No direct comparisons of alternative AIs in the adjuvant setting are reported, although indirect comparisons may be feasible. Future evaluations of treatment strategies over the entire course of the disease may also be needed...
  5. ncbi request reprint A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK
    J Karnon
    School of Health and Related Research, University of Sheffield, Regent Court, Regent Street, Sheffield, S1 4DA, UK
    Int J Cardiol 109:307-16. 2006
    ....
  6. ncbi request reprint Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK
    Jon Karnon
    School of Health and Related Research ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    Curr Med Res Opin 21:101-12. 2005
    ..To assess the long term cost effectiveness of clopidogrel monotherapy compared with acetylsalicylic acid (aspirin; ASA) monotherapy in patients at risk of secondary occlusive vascular events (OVEs) in the UK...
  7. ncbi request reprint Developing a relativities approach to valuing the prevention of non-fatal work-related accidents and ill health
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, UK
    Health Econ 14:1103-15. 2005
    ..Potential amendments are suggested, but the general relativities approach warrants further investigation for the valuation of non-fatal work-related accidents and ill health...
  8. ncbi request reprint A critique and impact analysis of decision modeling assumptions
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Med Decis Making 27:491-9. 2007
    ..A case study model is analyzed to illustrate the quantitative impact of 3 of the issues...
  9. ncbi request reprint A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer
    J Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Ann Oncol 14:1629-33. 2003
    ..These newer therapies are more expensive, and will gain greater acceptance if they can demonstrate cost-effectiveness...
  10. ncbi request reprint Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation
    Jonathan Karnon
    Health Economics Research Group, Brunel University, UK
    Health Econ 12:837-48. 2003
    ..These results indicate that the use of DES may be beneficial only when the available data demonstrates particular characteristics...
  11. doi request reprint Modelling the expected net benefits of interventions to reduce the burden of medication errors
    Jonathan Karnon
    Department of Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, UK
    J Health Serv Res Policy 13:85-91. 2008
    ....
  12. ncbi request reprint Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Regent Street, Sheffield, S1 4DA, UK
    Eur J Health Econ 9:171-83. 2008
    ..Though the respective confidence intervals show significant overlap, letrozole has a 95% probability of being more cost-effective than tamoxifen at a 20,000pounds QALY value, whilst anastrozole has an 85% probability...
  13. doi request reprint Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation)
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    J Eval Clin Pract 15:299-306. 2009
    ..The aim of this study is to assess the incremental costs and effects [measured as quality adjusted life years (QALYs)] of a range of such interventions for which evidence of effectiveness exists...
  14. ncbi request reprint Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation
    Jonathan Karnon
    Health Economics Research Group, Brunel University, Uxbridge, Middlesex, United Kingdom
    Pharmacoeconomics 20:119-37. 2002
    ..There remains uncertainty around the appropriate choice of adjuvant therapies to offer postmenopausal women with node-positive early breast cancer...
  15. doi request reprint Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?
    Jonathan Karnon
    University of Sheffield, Sheffield, UK
    Appl Health Econ Health Policy 7:1-9. 2009
    ....
  16. ncbi request reprint Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
    Nick Bansback
    ScHARR Technology Assessment Group, School of Health and Related Research, University of Sheffield, Regent Court, 40 Regent Street, S1 4DA Sheffield, UK
    Eur J Health Econ 5:188-9. 2004
  17. ncbi request reprint A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients
    Jon Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, England
    Pharmacoeconomics 21:513-25. 2003
    ..Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first-line hormonal therapy for patients with advanced breast cancer...
  18. ncbi request reprint Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Breast Cancer Res Treat 108:375-87. 2008
    ....
  19. doi request reprint Cost-utility analysis of screening high-risk groups for anal cancer
    Jonathan Karnon
    School of Population Health and Clinical Practice, University of Adelaide, Adelaide, SA 5005, Australia
    J Public Health (Oxf) 30:293-304. 2008
    ..Cost-utility analysis of screening for anal cancer in high-risk groups from a UK perspective...
  20. ncbi request reprint Planning the efficient allocation of research funds: an adapted application of a non-parametric Bayesian value of information analysis
    Jonathan Karnon
    Health and Safety Laboratory, Broad Lane, Sheffield S3 7HQ, UK
    Health Policy 61:329-47. 2002
    ....
  21. ncbi request reprint Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
    Thomas E Delea
    Policy Analysis Inc, 4 Davis Court, Brookline, MA 02245, USA
    Am J Manag Care 12:374-86. 2006
    ..To estimate the cost-effectiveness of extended adjuvant letrozole in postmenopausal women with early breast cancer and estrogen or progesterone receptor-positive tumors who had completed 5 years of adjuvant tamoxifen...
  22. ncbi request reprint Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States
    Nick Bansback
    Centre for Health Evaluation and Outcome Sciences, St Paul s Hospital, Vancouver, British Columbia, Canada
    Pharmacoeconomics 26:395-408. 2008
    ..Further research is also required to explore the advantages in using either continuous or discrete health states...